In the pharmaceutical industry, financial analysis is like a company's "health check report," clearly reflecting its operational status, financial health, and future development trends. As competition in the pharmaceutical market intensifies, companies face challenges in cost control, R&D investment, market expansion, and more. Accurate financial analysis can help corporate management make scientific decisions, optimize resource allocation, and enhance the company's core competitiveness.

(I) Characteristics of the Pharmaceutical Industry and its Link to Financial Analysis

The pharmaceutical industry is characterized by high investment, high risk, long cycles, and high returns. From new drug development to product launch, it often takes several years or even decades, with investments amounting to hundreds of millions. This requires companies to pay special attention to R&D cost accounting, risk assessment, and the time value of money in their financial analysis. For example, Hengrui Medicine, a leading enterprise in China's pharmaceutical industry, invests a significant proportion of its operating revenue in R&D each year. Through scientific financial analysis, Hengrui Medicine can reasonably plan its R&D budget , evaluate the feasibility of R&D projects, and ensure continuous development driven by innovation.

(II) Impact of Financial Analysis on Pharmaceutical Enterprise Decision-Making

Financial analysis provides crucial support for decision-making in pharmaceutical companies. In terms of investment decisions, companies need to evaluate the profitability, solvency, and risk level of new investment projects through financial analysis. For instance, when a company considers acquiring a small pharmaceutical R&D firm, it needs to conduct an in-depth analysis of the target company's financial statements , including the balance sheet, income statement, and cash flow statement, to determine if the acquisition price is reasonable and if it can bring synergistic effects to the company post-acquisition. In terms of operational decisions, financial analysis can help companies optimize production processes, control costs, and formulate reasonable pricing strategies. Taking Fosun Pharma as an example, by analyzing the cost-effectiveness of different products, Fosun Pharma can adjust its product structure, concentrate resources on developing high-value-added products, and improve the company's overall profitability.

Although financial analysis is crucial in the pharmaceutical industry, there are still some pain points that restrict the effectiveness and value of financial analysis.

(I) Large and Complex Data Volume, High Integration Difficulty

Pharmaceutical companies are involved in a wide range of business activities, including R&D, production, sales, and procurement, with each link generating a large amount of data. This data is not only vast but also diverse in format and scattered in sources. For example, R&D department data may exist in the form of experiment reports and research papers, production department data in production records and quality inspection reports, and sales department data in sales orders and customer information. Integrating and analyzing this data requires a significant amount of time and effort.

(II) Numerous Financial Indicators, Single Analysis Dimension

Common financial indicators in the pharmaceutical industry include profitability indicators (e.g., gross profit margin, net profit margin), solvency indicators (e.g., debt-to-asset ratio, current ratio), and operating capability indicators (e.g., inventory turnover ratio, accounts receivable turnover ratio). However, in actual analysis, many companies often only focus on a few common indicators, lacking a comprehensive and in-depth analysis of financial indicators. For example, some companies only focus on changes in gross profit margin, while ignoring factors such as cost structure and product mix behind the gross profit margin. Such a single analysis dimension makes it difficult to fully reflect the company's financial status and operating results.

(III) Traditional Financial Analysis Methods, Lack of Innovation

Currently, most pharmaceutical companies still employ relatively traditional financial analysis methods, primarily ratio analysis and trend analysis. While these methods are simple and easy to understand, they have certain limitations. For example, ratio analysis can only reflect a company's financial status at a specific point in time and cannot predict its future development trends; trend analysis requires a long period of data accumulation, which may not accurately reflect the development changes for emerging pharmaceutical companies or those in rapid growth stages.

Modern pharmaceutical financial analysis tools offer effective solutions to the three major pain points in pharmaceutical financial analysis.

(I) Data Integration and Visualization Tools

Data integration and visualization tools can help companies quickly integrate data from different departments and systems, and display it in intuitive chart forms. For example, Tableau is a powerful data visualization tool that can connect to various data sources, including databases and Excel spreadsheets. Through simple drag-and-drop operations, it can generate various charts, such as bar charts, line charts, and pie charts. Companies can use Tableau to integrate data from R&D, production, sales, and other departments to visually display the company's operational status and trends in financial indicators.

Taking a medium-sized pharmaceutical company as an example, before using Tableau, the finance department had to spend a lot of time exporting data from different systems, then manually organizing and analyzing it. Due to the large and complex data volume, data errors and inconsistencies often occurred. After using Tableau, the finance department can directly connect to the databases of various systems, obtain data in real-time, and analyze it through visual charts. This not only improved data accuracy and timeliness but also significantly saved the time and effort of financial personnel.

(II) Multi-Dimensional Financial Analysis Tools

Multi-dimensional financial analysis tools can analyze financial data from multiple dimensions, helping companies gain a comprehensive understanding of their financial status and operating results. For example, Power BI, a business intelligence tool launched by Microsoft, supports multi-dimensional data analysis. It can analyze financial data from different perspectives through features like slicers and filters. Companies can use Power BI to analyze financial data for different products, regions, and customers, identify the most profitable products, regions, and customers, and provide more targeted recommendations for corporate decision-making.

Taking a large pharmaceutical group as an example, the group owns multiple subsidiaries and product lines. Before using Power BI, it was difficult for the group headquarters to conduct a comprehensive and in-depth analysis of the financial status of each subsidiary and product line. After using Power BI, the group headquarters can use multi-dimensional data analysis to understand the real-time changes in financial indicators such as revenue, costs, and profits of each subsidiary and product line, and conduct horizontal and vertical comparisons. This not only helps the group headquarters identify problems in a timely manner but also provides a scientific basis for the group's strategic planning and resource allocation.

(III) Intelligent Financial Analysis Tools

Intelligent financial analysis tools leverage artificial intelligence and big data technology to conduct in-depth mining and analysis of financial data, predicting future development trends for companies. For example, IBM Watson Analytics is an AI-based financial analysis tool that can understand user questions through natural language processing technology and automatically generate analysis reports. Companies can use IBM Watson Analytics to analyze historical financial data, identify key factors affecting the company's financial status and operating results, and predict future development trends.

Taking an emerging pharmaceutical company as an example, this company is developing an innovative drug. During the R&D process, the company needs to forecast and analyze R&D costs, market prospects, and other factors. After using IBM Watson Analytics, the company can input R&D data, market data, etc., into the system, which will automatically analyze and generate prediction reports. This not only helps the company reduce R&D risks but also provides strong support for the company's financing and market promotion.

To better illustrate the application effects of pharmaceutical financial analysis tools, we will take a well-known pharmaceutical company as an example to describe the changes before and after its use of financial analysis tools.

(I) Company Background

The company is a large pharmaceutical enterprise integrating R&D, production, and sales, with main products including chemical drugs, traditional Chinese medicines, and biological drugs. As the company's scale continued to expand, it faced problems such as large data volumes, high difficulty in financial analysis, and low decision-making efficiency.

(II) Prominence of Problems

Before using financial analysis tools, the company's financial analysis had the following problems:

– Data integration difficulties: The company's R&D, production, and sales departments used different systems, leading to inconsistent data formats and high integration complexity.

– Single analysis dimension: The finance department primarily focused on a few common financial indicators, lacking comprehensive and in-depth analysis of financial data.

– Traditional analysis methods: The company's financial analysis methods were mainly ratio analysis and trend analysis, which could not predict future development trends.

These problems led to low decision-making efficiency, inability to timely identify and solve problems, and consequently affected the company's development.

(III) Innovativeness of Solutions

To solve these problems, the company introduced a set of advanced pharmaceutical financial analysis tools, including data integration and visualization tools, multi-dimensional financial analysis tools, and intelligent financial analysis tools.